Thermo Fisher expects lasting benefits to bill targeting Chinese service...
Thermo Fisher said it will be a “long-term beneficiary” of biopharma customers localizing their supply chains, given most of its network is based in the US and Europe. Clients are thinking more...
View ArticleNeurocrine launches CAH rare disease education campaign ahead of FDA submission
Neurocrine Biosciences’ newly-debuted campaign acknowledges the frustration that congenital adrenal hyperplasia (CAH) patients, families and endocrinologists often feel. The “What the C@H?!” theme is a...
View ArticleSen. Sanders launches probe of Novo's Wegovy and Ozempic pricing
Sen. Bernie Sanders (I-VT) is ramping up his campaign against what he says are “outrageously high” list prices for Novo Nordisk’s weight loss and diabetes blockbusters Wegovy and Ozempic. The senator...
View ArticleFollowing lower-than-expected profits, Evotec plans to cut costs, completes...
Evotec announced a “reset” to its business plan as it reported financial results Wednesday, following a year in which many contract drug manufacturers have struggled. Mario Polywka The German company...
View ArticleCidara buys back flu rights, sells antifungal and inks $240M PIPE
Cidara Therapeutics announced several sweeping moves on Wednesday afternoon to bring an influenza drug back in-house and raise money from investors to back the program. The San Diego biotech said it...
View ArticleBioMarin's Roctavian struggles continue. Is a divestment in the future?
Less than a year into a rocky rollout for its gene therapy Roctavian, BioMarin is now talking about whether the product might be a better fit outside the company, and cutting several pipeline programs....
View ArticleWalgreens will build out specialty pharmacy business, leaning into drug and...
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) Walgreens said Thursday it’s getting into cell and gene therapy pharmacy services and bringing its...
View ArticleAstellas' Friedreich’s ataxia gene therapy cleared for clinical study after...
After hitting a speed bump in its first attempt at developing a gene therapy for Friedreich’s ataxia, Astellas is ready to put a new version in the clinic. On Thursday, the Japanese drugmaker announced...
View ArticleSanofi spotlights early-stage cancer assets, counts on grandfather clause on...
Sanofi is keeping an early pipeline of oncology projects even as it axed clinical-stage programs and reallocated resources to immunology, CEO Paul Hudson told reporters Thursday morning. Hudson also...
View ArticleBristol Myers plans $1.5B in cost cuts as CEO promises more 'agile' company
The “transition period” that Bristol Myers Squibb CEO Chris Boerner promised was coming to the company appears to have arrived. On Thursday, the pharma giant said it would undertake $1.5 billion in...
View ArticleRegeneron and Mammoth strike $100M deal to pair tiny CRISPR editors with new...
Regeneron is expanding its genetic medicine efforts and will work with California startup Mammoth Biosciences on gene-editing programs reaching parts of the human body beyond the liver, the companies...
View ArticleAstraZeneca’s Pascal Soriot says new rise in pay is ‘really about’ potential...
AstraZeneca CEO Pascal Soriot vigorously defended his recently secured $23.5 million pay package, citing the UK pharma’s need to compete for talent. “It really is about making the company competitive...
View ArticleMerck KGaA to expand German headquarters with €300M+ research center
Merck KGaA is allocating over €300 million ($321.8 million) to build a new research building at its headquarters in Darmstadt, Germany to study technologies for its life science business. By 2027, the...
View ArticleAstellas cuts a bispecific in cancer and a mitochondria-focused asset from...
Astellas said it has removed a Phase 1 cancer asset as well as a small molecule that came from its Mitobridge acquisition. The Japanese pharma will no longer test the TSPAN8 and CD3 bispecific known as...
View ArticleCerevance's $47M raise; Parexel's AI pact
Plus, news about Intra-Cellular: Cerevance adds $47 million to Series B: The neurological disease biotech’s series B-1 raise now sits at $98 million, with investments from Agent Capital,...
View ArticleBristol Myers outlines ‘about 12’ pipeline cuts as it executes major cutbacks
As part of its sweeping $1.5 billion cost-cutting measure, Bristol Myers Squibb is culling “about 12” programs from its pipeline, CMO Samit Hirawat said Thursday morning. The programs will either be...
View ArticleMerck records yet another strong quarter for Keytruda
Merck posted yet another strong quarter on the back of its cancer therapy Keytruda, in what’s becoming almost a routine event for the New Jersey drugmaker. “New quarter, same Merck outperformance,” BMO...
View ArticleSage focuses on successful launch of postpartum depression drug
Sage Therapeutics is doubling down on the “blockbuster potential” of its postpartum depression drug Zurzuvae, expanding professional promotions and taking steps toward a direct-to-consumer launch after...
View ArticleAstraZeneca on emerging markets, GLP-1 plans and why it’s selective about...
AstraZeneca put the spotlight on its near-20% revenue growth during first-quarter earnings, driven in part by its success in emerging markets. Executives on the company’s analyst call discussed...
View ArticleGSK accuses Pfizer and BioNTech of mRNA patent infringement
GSK says it is owed a portion of Pfizer and BioNTech’s Covid-19 vaccine sales in the latest patent suit filed against the Comirnaty partners. In a lawsuit filed in federal court in Delaware Thursday,...
View Article